ReviewClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2023
Anhedonia and Depressive Disorders.
Review in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 3 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Examining the relationship between pre-treatment anhedonia and treatment outcomes in individuals with anxiety or depression: A systematic review.Journal of affective disorders · 2026Pooled it
- Purpose in life and depressive symptoms: An individual-participant meta-analysis of >500,000 participants across six world regions.Journal of affective disorders · 2026Pooled it
- Interventions for suicidal and self-injurious related behaviors in adolescents with psychiatric disorders: a systematic review and meta-analysis.Translational psychiatry · 2025Pooled it
- Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD.European psychiatry : the journal of the Association of European Psychiatrists · 2026Trial
- Positive Affect Treatment for Depression, Anxiety, and Low Positive Affect: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Selective KOR antagonist alters functional patch sizes in individualized brain system: results from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Exploring the Role of Reward Functioning in the Overlap of Post-Traumatic Stress and Cocaine Use Disorder.Substance use & misuse · 2025Trial
- Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-Release Tablets in Depression With Anhedonia: A Single-Arm, Multicenter Clinical Study.Depression and anxiety · 2025Trial
- A Phase 2 Randomized Trial of NBI-1065846 (TAK-041) in Patients With Anhedonia Associated With Major Depressive Disorder: Results of the TERPSIS Study.Journal of clinical psychopharmacologyTrial
- Treatment-resistant Depression in the Post-ketamine Era: Unmet Needs beyond Rapid Response.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Review
- Towards precision psychiatry: initial foundations and future directions.Nature reviews. Drug discovery · 2026Review
- Dynamic coupling of emotion and pain: from perception to affective response.The Korean journal of pain · 2026Review
- Link Between Anhedonia, Reward Dysfunction, and Eating Behavior Across Mental and Physical Health Conditions: A Narrative Review.Nutrients · 2026Review
- Molecular Characterization of the Progressive Landscape of Depression.bioRxiv : the preprint server for biology · 2026Article
- Patient perspectives on the challenges, obstacles, and opportunities in discussing and managing anhedonia in major depressive disorder (MDD): a focus group study.Annals of general psychiatry · 2026Article
- From uniform pharmacotherapy to precision psychiatry: reinforcement sensitivity associations with SSRI outcomes.Psychopharmacology · 2026Article
- Brain network localization of anhedonia.Translational psychiatry · 2026Article
- Reward Motivation Adaptation Deficits Are Specific to Co-Occurring Subclinical Depression and Anhedonia.Behavioral sciences (Basel, Switzerland) · 2026Article
- The relationship between negative life events and anhedonia among patients with major depressive disorder: chain mediation of insomnia and dysfunctional attitudes.BMC psychiatry · 2026Article
- Anhedonia and its sub-component processes predict clinically significant symptoms of Major Depressive Disorder (MDD) and loneliness in young people.The British journal of clinical psychology · 2026Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anhedonia is a core symptom of depression and of several psychiatric disorders. Anhedonia has however expanded from its original definition to encompass a spectrum of reward processing deficits that received much interest in the last decades. It is a relevant risk factor for possible suicidal behaviors, and that it may operate as an independent risk factor for suicidality apart from the episode severity. Anhedonia has also been linked to inflammation with a possible reciprocal deleterious effect on depression. Its neurophysiological bases mainly include alterations in striatal and prefrontal areas, with dopamine being the most involved neurotransmitter. Anhedonia is thought to have a significant genetic component and polygenic risk scores are a possible tool for predicting an individual's risk for developing anhedonia. Traditional antidepressants, such as selective serotonin reuptake inhibitors, showed a limited benefit on anhedonia, also considering their potential pro-anhedonic effect in some subjects. Other treatments may be more effective in treating anhedonia, such as agomelatine, vortioxetine, ketamine and transcranial magnetic stimulation. Psychotherapy is also widely supported, with cognitive-behavioral therapy and behavioral activation both showing benefit. In conclusion, a large body of evidence suggests that anhedonia is, at least partially, independent from depression, therefore it needs careful assessment and targeted treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.